Free Trial

Xenon Pharmaceuticals (XENE) News Today

$42.06
-0.03 (-0.07%)
(As of 09:57 AM ET)
Xenon Pharmaceuticals logo with Medical background
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC decreased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 737,173 shares of the biopharmaceutical company's stock after
Xenon Pharmaceuticals logo with Medical background
GSA Capital Partners LLP Invests $930,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
GSA Capital Partners LLP purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 21,614 shares of the biopharmaceutical company's stock, valued at approximate
Xenon Pharmaceuticals logo with Medical background
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options.
Xenon Pharmaceuticals logo with Medical background
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6%
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6%
Xenon Pharmaceuticals logo with Medical background
Goldman Sachs Group Inc. Has $17.33 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Goldman Sachs Group Inc. grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 47.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 376,302 shares of the biopharmaceutical company's st
Xenon Pharmaceuticals logo with Medical background
Wellington Management Group LLP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Wellington Management Group LLP increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 140.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,162,654 shares of the biopharmaceutical company's s
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Perceptive Advisors LLC
Perceptive Advisors LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 78.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,100,748 shares of the biopharmaceu
PFM Health Sciences LP Buys 114,269 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
PFM Health Sciences LP raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 145.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 192,856 shares of the biopharmaceutical company's stock after purchasing an a
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by First Light Asset Management LLC
First Light Asset Management LLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 173.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,645,490 shares of the biopharmaceutical company's stock after buying an additional 1,043,420
Braidwell LP Reduces Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Braidwell LP trimmed its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 21.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,647,311 shares of the biopharmaceutical
Avoro Capital Advisors LLC Acquires 766,666 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Avoro Capital Advisors LLC raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,666,666 shares of
Vestal Point Capital LP Invests $8.06 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Vestal Point Capital LP purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 175,000 shares of the biopharmaceutical company's stock, valued at approximately $8,060
Capital World Investors Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Capital World Investors lifted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 17.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,681,537 shares of the biopharmaceutical company's stock after purchasing an additional 406,563 shares
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stake Lifted by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 53.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 460,000 shares of the biopharmaceutical company's stock after acquiring an additiona
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 1-year target pr
Stock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the typical daily volume of 165 put options.
Franklin Resources Inc. Buys 121,213 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Franklin Resources Inc. lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 70.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 293,825 shares of the biopharmaceutical company's stock a
Stocks in play: Satellos Bioscience Inc.
Westfield Capital Management Co. LP Invests $10.94 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Westfield Capital Management Co. LP acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 237,495 shares of the biopharmaceutic
Bridger Management LLC Purchases Shares of 146,800 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Bridger Management LLC purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 146,800 shares of the biopharmaceutical company's stock,
24,000 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Purchased by Jump Financial LLC
Jump Financial LLC bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 24,000 shares of the biopharmaceutical compan
Stock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock traders acquired 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average volume of 165 put options.
Nicholas Investment Partners LP Has $4.04 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Nicholas Investment Partners LP trimmed its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 89.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,752 shares of the biopharmaceutical company's sto
Citigroup Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $60.00
Citigroup lowered their price objective on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating for the company in a research report on Friday.
Xenon Pharmaceuticals (NASDAQ:XENE) Given Buy Rating at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and set a $62.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday.
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings Results, Beats Estimates By $0.07 EPS
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.07. The company had revenue of $1.00 million during the quarter. During the same quarter in the prior year, the firm earned ($0.63) EPS. The firm's revenue was up .0% compared to the same quarter last year.
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst Downgrade
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade
Xenon Pharmaceuticals: Q1 Earnings Snapshot
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 34.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 793,954 shares of the
Xenon Pharmaceuticals (XENE) Set to Announce Earnings on Thursday
Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.
abrdn plc Acquires Shares of 32,036 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
abrdn plc bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 32,036 shares of the biopharmaceutical company's stock, valued at approximately $1,476,000. S
Jennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Jennison Associates LLC lifted its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 164.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 566,396 shares of the biopharmaceutical
Federated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Federated Hermes Inc. bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 346,596 shares of the biopharmaceutical compan
Get Xenon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

Home To The World’s Largest High-Grade Uranium Deposits (Ad)

Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.

Click here to see why this could be one of the greatest periods for the nuclear industry ever

XENE Media Mentions By Week

XENE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

XENE
News Sentiment

1.19

0.93

Average
Medical
News Sentiment

XENE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

XENE Articles
This Week

3

3

XENE Articles
Average Week

Get Xenon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:XENE) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners